CHOPN +
CHOPN+ Registry is a non-interventional, multicenter, observational, prospective database focused on the collection of data on patients receiving biological therapy and builds upon the CHOPN Registry.
Project Objectives
Chronic Obstructive Pulmonary Disease (COPD) is a serious, progressive, and incurable condition characterized by irreversible airflow obstruction and gradual destruction of lung tissue. The most common cause is smoking; however, genetic predisposition, long-term exposure to harmful substances, and recurrent respiratory infections also play a significant role.
COPD is among the leading causes of morbidity and mortality worldwide and represents a substantial burden on healthcare systems as well as on patients’ quality of life.
Standard treatment primarily includes inhaled bronchodilators (LABA, LAMA), inhaled corticosteroids, pulmonary rehabilitation, and oxygen therapy. Nevertheless, in a proportion of patients, recurrent acute exacerbations, progression of lung damage, and insufficient symptom control persist despite maximal inhaled therapy.
It is precisely in these patients that an opportunity for biological therapy emerges. Biological agents target specific inflammatory mechanisms involved in the development and progression of COPD.
In a subgroup of patients with so-called eosinophilic inflammation (type 2 inflammation), increased activity of interleukins IL-4 and IL-13 has been demonstrated, leading to more frequent exacerbations and a faster decline in lung function. Blocking these pathways with biological therapy can reduce the number of exacerbations, improve lung function, and consequently enhance patients’ quality of life.
According to current recommendations (GOLD Strategy 2026), two therapeutic molecules targeting type 2 inflammation are listed:
- dupilumab
- mepolizumab
Initiation of the CHOPN+ Registry
The initiation of the registry is a complex process aimed at creating a unified and methodologically robust platform for the systematic collection of clinical data. In the first phase, it is essential to establish an organizational structure that defines the roles of individual team members.
This is followed by the definition of objectives and methodology, including the specification of the scientific and clinical aims of the registry and the determination of inclusion criteria for patient enrollment.
Equally important are ethical and legal aspects, including approval by an ethics committee, preparation of informed consent for patients, engagement of participating centers, and the establishment of rules for data sharing and publication.